The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archivos de la Sociedad Española de Oftalmología 2017-05, Vol.92 (5), p.245-246
Hauptverfasser:	Navarro-Navarro, A, Salom, D, Martínez-Toldos, J J, Udaondo, P, Fernández-Martínez, C, Gutiérrez-Arias, L, Hervás, A, Rodrigo, R
Format:	Artikel
Sprache:	eng ; spa
Schlagworte:	Bevacizumab - economics Bevacizumab - therapeutic use Cost-Benefit Analysis Diabetic Retinopathy - drug therapy Diabetic Retinopathy - economics Humans Macular Edema - drug therapy Macular Edema - economics Ranibizumab - economics Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - economics Recombinant Fusion Proteins - therapeutic use Spain
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!